Metropolitan Life Insurance Company (MetLife)’s Lyell Immunopharma LYEL Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio LYEL Stock Details LYEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-331	Closed	-$14.8K	–	1219
2024 Q1	$14.8K	Buy	331 +14	+4%	+$599	﹤0.01%	1995
2023 Q4	$12.3K	Sell	317 -175	-36%	-$6.3K	﹤0.01%	2111
2023 Q3	$14.5K	Hold	492	–	–	﹤0.01%	2044
2023 Q2	$31.3K	Hold	492	–	–	﹤0.01%	1693
2023 Q1	$23.2K	Sell	492 -45	-8%	-$2.41K	﹤0.01%	1807
2022 Q4	$37.3K	Hold	537	–	–	﹤0.01%	1651
2022 Q3	$78.7K	Hold	537	–	–	﹤0.01%	1165
2022 Q2	$70K	Buy	537 +42	+8%	+$4.29K	﹤0.01%	1290
2022 Q1	$50K	Buy	+495	New	+$60K	﹤0.01%	1590
2021 Q4	–	Sell	-390	Closed	-$116K	–	2810
2021 Q3	$116K	Buy	+390	New	+$117K	﹤0.01%	2443

Other funds holding LYEL

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

OPL

Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

WuXi AppTec Shanghai, China $19M AUM 20.22% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s LYEL Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Lyell Immunopharma (LYEL) in Q2 2024, closing a stake of 331 shares — an estimated $14.8K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in LYEL in Q3 2021 and held it in 10 quarters. The position peaked at $116K in Q3 2021. 119 funds tracked by Wall St. Rank hold LYEL as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining Lyell Immunopharma position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 331 Lyell Immunopharma shares in Q2 2024, an estimated $14.8K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Lyell Immunopharma in Q3 2021 and held it in 10 quarters.
Metropolitan Life Insurance Company (MetLife)'s Lyell Immunopharma position peaked at $116K in Q3 2021.
119 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.